Dexmedetomidine as an Anesthetic Adjuvant in Cardiac Surgery: a Cohort Study

ABSTRACT Objective: α-2-agonists cause sympathetic inhibition combined with parasympathetic activation and have other properties that could be beneficial during cardiac anesthesia. We evaluated the effects of dexmedetomidine as an anesthetic adjuvant compared to a control group during cardiac surgery. Methods: We performed a retrospective analysis of prospectively collected data from all adult patients (> 18 years old) undergoing cardiac surgery. Patients were divided into two groups, regarding the use of dexmedetomidine as an adjuvant intraoperatively (DEX group) and a control group who did not receive α-2-agonist (CON group). Results: A total of 1302 patients who underwent cardiac surgery, either coronary artery bypass graft or valve surgery, were included; 796 in the DEX group and 506 in the CON group. Need for reoperation (2% vs. 2.8%, P=0.001), type 1 neurological injury (2% vs. 4.7%, P=0.005) and prolonged hospitalization (3.1% vs. 7.3%, P=0.001) were significantly less frequent in the DEX group than in the CON group. Thirty-day mortality rates were 3.4% in the DEX group and 9.7% in the CON group (P<0.001). Using multivariable Cox regression analysis with in hospital death as the dependent variable, dexmedetomidine was independently associated with a lower risk of 30-day mortality (odds ratio [OR]=0.39, 95% confidence interval [CI]: 0.24-0.65, P≤0.001). The Logistic EuroSCORE (OR=1.05, 95% CI: 1.02-1.10, P=0.004) and age (OR=1.03, 95% CI: 1.01-1.06, P=0.003) were independently associated with a higher risk of 30-day mortality. Conclusion: Dexmedetomidine used as an anesthetic adjuvant was associated with better outcomes in patients undergoing coronary artery bypass graft and valve surgery. Randomized prospective controlled trials are warranted to confirm our results.

Saved in:
Bibliographic Details
Main Authors: Brandão,Paulo Gabriel Melo, Lobo,Francisco Ricardo, Ramin,Serginando Laudenir, Sakr,Yasser, Machado,Mauricio Nassau, Lobo,Suzana Margareth
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Cirurgia Cardiovascular 2016
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-76382016000300213
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0102-76382016000300213
record_format ojs
spelling oai:scielo:S0102-763820160003002132016-10-04Dexmedetomidine as an Anesthetic Adjuvant in Cardiac Surgery: a Cohort StudyBrandão,Paulo Gabriel MeloLobo,Francisco RicardoRamin,Serginando LaudenirSakr,YasserMachado,Mauricio NassauLobo,Suzana Margareth Dexmedetomidine Cardiovascular Surgical Procedures Adjuvants Anesthesia ABSTRACT Objective: α-2-agonists cause sympathetic inhibition combined with parasympathetic activation and have other properties that could be beneficial during cardiac anesthesia. We evaluated the effects of dexmedetomidine as an anesthetic adjuvant compared to a control group during cardiac surgery. Methods: We performed a retrospective analysis of prospectively collected data from all adult patients (> 18 years old) undergoing cardiac surgery. Patients were divided into two groups, regarding the use of dexmedetomidine as an adjuvant intraoperatively (DEX group) and a control group who did not receive α-2-agonist (CON group). Results: A total of 1302 patients who underwent cardiac surgery, either coronary artery bypass graft or valve surgery, were included; 796 in the DEX group and 506 in the CON group. Need for reoperation (2% vs. 2.8%, P=0.001), type 1 neurological injury (2% vs. 4.7%, P=0.005) and prolonged hospitalization (3.1% vs. 7.3%, P=0.001) were significantly less frequent in the DEX group than in the CON group. Thirty-day mortality rates were 3.4% in the DEX group and 9.7% in the CON group (P<0.001). Using multivariable Cox regression analysis with in hospital death as the dependent variable, dexmedetomidine was independently associated with a lower risk of 30-day mortality (odds ratio [OR]=0.39, 95% confidence interval [CI]: 0.24-0.65, P≤0.001). The Logistic EuroSCORE (OR=1.05, 95% CI: 1.02-1.10, P=0.004) and age (OR=1.03, 95% CI: 1.01-1.06, P=0.003) were independently associated with a higher risk of 30-day mortality. Conclusion: Dexmedetomidine used as an anesthetic adjuvant was associated with better outcomes in patients undergoing coronary artery bypass graft and valve surgery. Randomized prospective controlled trials are warranted to confirm our results.info:eu-repo/semantics/openAccessSociedade Brasileira de Cirurgia CardiovascularBrazilian Journal of Cardiovascular Surgery v.31 n.3 20162016-06-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-76382016000300213en10.5935/1678-9741.20160043
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Brandão,Paulo Gabriel Melo
Lobo,Francisco Ricardo
Ramin,Serginando Laudenir
Sakr,Yasser
Machado,Mauricio Nassau
Lobo,Suzana Margareth
spellingShingle Brandão,Paulo Gabriel Melo
Lobo,Francisco Ricardo
Ramin,Serginando Laudenir
Sakr,Yasser
Machado,Mauricio Nassau
Lobo,Suzana Margareth
Dexmedetomidine as an Anesthetic Adjuvant in Cardiac Surgery: a Cohort Study
author_facet Brandão,Paulo Gabriel Melo
Lobo,Francisco Ricardo
Ramin,Serginando Laudenir
Sakr,Yasser
Machado,Mauricio Nassau
Lobo,Suzana Margareth
author_sort Brandão,Paulo Gabriel Melo
title Dexmedetomidine as an Anesthetic Adjuvant in Cardiac Surgery: a Cohort Study
title_short Dexmedetomidine as an Anesthetic Adjuvant in Cardiac Surgery: a Cohort Study
title_full Dexmedetomidine as an Anesthetic Adjuvant in Cardiac Surgery: a Cohort Study
title_fullStr Dexmedetomidine as an Anesthetic Adjuvant in Cardiac Surgery: a Cohort Study
title_full_unstemmed Dexmedetomidine as an Anesthetic Adjuvant in Cardiac Surgery: a Cohort Study
title_sort dexmedetomidine as an anesthetic adjuvant in cardiac surgery: a cohort study
description ABSTRACT Objective: α-2-agonists cause sympathetic inhibition combined with parasympathetic activation and have other properties that could be beneficial during cardiac anesthesia. We evaluated the effects of dexmedetomidine as an anesthetic adjuvant compared to a control group during cardiac surgery. Methods: We performed a retrospective analysis of prospectively collected data from all adult patients (> 18 years old) undergoing cardiac surgery. Patients were divided into two groups, regarding the use of dexmedetomidine as an adjuvant intraoperatively (DEX group) and a control group who did not receive α-2-agonist (CON group). Results: A total of 1302 patients who underwent cardiac surgery, either coronary artery bypass graft or valve surgery, were included; 796 in the DEX group and 506 in the CON group. Need for reoperation (2% vs. 2.8%, P=0.001), type 1 neurological injury (2% vs. 4.7%, P=0.005) and prolonged hospitalization (3.1% vs. 7.3%, P=0.001) were significantly less frequent in the DEX group than in the CON group. Thirty-day mortality rates were 3.4% in the DEX group and 9.7% in the CON group (P<0.001). Using multivariable Cox regression analysis with in hospital death as the dependent variable, dexmedetomidine was independently associated with a lower risk of 30-day mortality (odds ratio [OR]=0.39, 95% confidence interval [CI]: 0.24-0.65, P≤0.001). The Logistic EuroSCORE (OR=1.05, 95% CI: 1.02-1.10, P=0.004) and age (OR=1.03, 95% CI: 1.01-1.06, P=0.003) were independently associated with a higher risk of 30-day mortality. Conclusion: Dexmedetomidine used as an anesthetic adjuvant was associated with better outcomes in patients undergoing coronary artery bypass graft and valve surgery. Randomized prospective controlled trials are warranted to confirm our results.
publisher Sociedade Brasileira de Cirurgia Cardiovascular
publishDate 2016
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-76382016000300213
work_keys_str_mv AT brandaopaulogabrielmelo dexmedetomidineasananestheticadjuvantincardiacsurgeryacohortstudy
AT lobofranciscoricardo dexmedetomidineasananestheticadjuvantincardiacsurgeryacohortstudy
AT raminserginandolaudenir dexmedetomidineasananestheticadjuvantincardiacsurgeryacohortstudy
AT sakryasser dexmedetomidineasananestheticadjuvantincardiacsurgeryacohortstudy
AT machadomauricionassau dexmedetomidineasananestheticadjuvantincardiacsurgeryacohortstudy
AT lobosuzanamargareth dexmedetomidineasananestheticadjuvantincardiacsurgeryacohortstudy
_version_ 1756429525598601216